
47 million-year-old bug is the oldest singing cicada fossil from Europe
Scientists recently described the insect as a new genus and species, using this fossil and one other that was nearly as well preserved, from the same site. Even though the specimens are female, their location on the cicada family tree suggests that males of this species could sing as modern cicadas do. Found in Germany decades ago, their presence there reveals that singing cicadas dispersed in Europe millions of years earlier than once thought.
The fossils are also the oldest examples of 'true' singing cicadas in the family Cicadidae, researchers reported April 29 in the journal Scientific Reports. Most modern cicadas belong to this family, including annual cicadas that appear every summer worldwide, as well as broods of black-bodied and red-eyed periodical cicadas, which emerge from May to June in eastern North America in cycles of 13 or 17 years. Brood XIV, one of the biggest broods, emerges across a dozen US states this year. Cicadas are found on every continent except Antarctica, and there are more than 3,000 species.
The fossil record for insects in general is abundant in just a few dozen locations, and while modern cicada species are numerous today, paleontologists have documented only 44 Cicadidae fossils. The earliest definitive fossil of a singing cicada was discovered in Montana and dates from 59 million to 56 million years ago, said lead study author Dr. Hui Jiang, a paleontologist and researcher with the Bonn Institute of Organismic Biology at the University of Bonn in Germany. Its newly described relative is the earliest singing cicada from Europe, Jiang told CNN in an email.
Related card
Cicadas rising: A visual guide to 2024's rare dual appearance
Because the body structures of the European fossils were so well preserved, scientists were able to assign the ancient insect to a modern tribe of cicadas called Platypleurini, 'which is today primarily distributed in tropical and subtropical regions of sub-Saharan Africa and Asia, but is absent from Europe,' Jiang said.
Prior research suggested that this lineage evolved in Africa about 30 million to 25 million years ago and dispersed from there, according to Jiang. 'This fossil pushes back the known fossil record of sound-producing cicadas in the tribe Platypleurini by approximately 20 million years, indicating that the diversification of this group occurred much earlier than previously recognized,' the researcher added.
The discovery hints that this group of cicadas evolved more slowly than prior estimates from molecular data proposed, said Dr. Conrad Labandeira, a senior research geologist and curator of fossil arthropods at the Smithsonian Museum of Natural History in Washington, DC.
'This suggests that older fossils of the Platypleurini are yet to be discovered,' said Labandeira, who was not involved in the research. 'Such discoveries would assist in providing better calibrations for determining a more realistic evolutionary rate.'
Researchers named the cicada Eoplatypleura messelensis. Its name refers to where the specimens were discovered: the Messel Pit in Germany, a rich fossil site dating to the Eocene epoch (57 million to 36 million years ago). Excavated in the 1980s, the fossils have since been in the collection of the Senckenberg Research Institute and Natural History Museum Frankfurt in Germany, said senior study author Dr. Sonja Wedmann, head of Senckenberg's paleoentomology department.
A very deep volcanic lake, with a bottom where no oxygen penetrated, once filled the Messel Pit. That environment created ideal conditions for fossilization, and fine-grain sediments from this former lake bed hold a variety of Eocene life, Wedmann told CNN in an email.
'The excellent preservation not only of insects, but of all groups of organisms, is the reason why Messel is an UNESCO world heritage site,' a designation it earned in 1995, Wedmann said.
The more complete of the two cicada fossils 'is one of the best preserved insects from the Messel pit fossil site,' Wedmann added. 'Senckenberg has a collection of over 20,000 fossil insects from Messel, and among these it stands out because of its really beautiful and complete preservation.'
In its overall head and body shape, E. messelensis strongly resembles modern cicadas. Its rostrum — a snoutlike mouth — is intact, but closer analysis is needed to tell whether it used the rostrum for feeding on plant tissues called xylem, as most modern cicadas do, Labandeira said.
E. messelensis also shows hints of colors and patterns in its wings. This feature camouflages modern cicadas as they cling to tree trunks, and it may have served a similar purpose for E. messelensis, according to Jiang.
However, E. messelensis differs from modern cicadas in subtle ways. For example, its forewings are broader and less elongated than those of species alive today, which may have affected how it flew.
Would the ancient cicada's call have sounded like those of its modern relatives? 'We can't know the exact song,' Jiang said. However, based on the cicada's body shape and placement in the singing cicada group, 'it likely produced sounds similar in function to modern cicadas.'
When Brood XIV emerges in the billions in the late spring and early summer of 2025, their calls will measure from 90 to 100 decibels — as loud as a subway train. Other types of cicadas produce an even bigger ruckus: Songs of the African cicada Brevisana brevis peak at nearly 107 decibels, about as loud as a jet taking off.
The volume of the ancient species' songs may have been even louder than that, Jiang said. The abdomen of E. messelensis is broader and larger than those of its modern relatives, suggesting that males could have had a larger resonating cavity. This cavity may have amplified sound from the vibrating structures in their abdomens, called tymbals, to produce a louder buzz.
'Of course, this is only a hypothesis,' Jiang added. 'Future studies on how morphology relates to sound production in modern cicadas will help to test it.'
Mindy Weisberger is a science writer and media producer whose work has appeared in Live Science, Scientific American and How It Works magazine.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
26 minutes ago
- Medscape
Cancer Risk in MMF-Treated Patients Differs by Indication
TOPLINE: Patients with dermatologic conditions showed a 74% lower risk for malignancy with mycophenolate mofetil (MMF) than transplant patients, a study found. METHODOLOGY: Researchers conducted a single-center retrospective chart of patients who had taken MMF for ≥ 5 years between 2012 and 2025 at Atrium Health Wake Forest Baptist Medical Center. The analysis included 126 patients (mean age, 64.2 years; 35.7% men) who received MMF for dermatologic conditions, 226 organ transplant recipients (mean age, 59.6 years; 61.5% men) who received MMF plus other immunosuppressive agents, and 296 patients (mean age, 64.1 year; 34.5% men) with dermatologic conditions who had no exposure to systemic immunosuppression. About two thirds of patients were White individuals and one fourth were Black individuals. Dermatologic patients received a mean daily MMF dose of 1390 mg over an average of 7.5 years, while transplant recipients received a lower mean daily dose of 807 mg for a mean duration of 9.9 years. Concomitant immunosuppressive therapy was administered to 40% of the patients with dermatologic conditions (MMF plus prednisone) and to 100% of transplant recipients (tacrolimus, prednisone, or cyclosporine). Researchers compared malignancy rates between the groups. TAKEAWAY: Overall, 9.5% of the dermatologic patients who received MMF developed malignancies compared with 36% of the transplant recipients (P < .0001); the risk for malignancy was 74% lower in dermatologic patients treated with MMF (95% CI, 0.1487-0.4518). No difference was found between dermatologic patients who received MMF vs those without exposure to systemic immunosuppression (8.4%). Cutaneous malignancies were significantly more common in transplant patients than in dermatologic patients who received MMF (26.5% vs 5.6%; P < .0001). The prevalence of urological/reproductive cancers was higher in transplant patients than dermatologic patients treated with MMF (9.3% vs 2.4%; P = .0143). IN PRACTICE: 'The use of MMF for dermatologic conditions does not appear to expose patients to the same malignancy risk as those treated with MMF and other chronic immunosuppressive treatments in the transplant setting and did not confer an elevated malignancy risk compared to dermatologic patients without systemic immunosuppression,' the authors of the study wrote. SOURCE: The study was led by Robin Yi, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, and was published online on July 17 in the Journal of the American Academy of Dermatology. LIMITATIONS: Limitations included the MMF dosing variability and small sample size. DISCLOSURES: The study did not receive any funding. One author reported receiving research, speaking and consulting support from numerous pharmaceutical companies including Eli Lilly, GlaxoSmithKline/Stiefel, AbbVie, and Janssen and disclosed being founder and part owner of Causa Research and holding stock in Sensal Health. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Llusern Scientific Announces Key Appointments to Strengthen its Executive Team
CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide CARDIFF, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, today announces the appointments of Bob Yang as Chief Medical Officer (CMO), Maddy Kennedy as Chief Financial Officer (CFO), and Mark Preston as Chief Technology Officer (CTO). These strategic appointments strengthen Llusern's leadership team as the company builds on its recent ISO 13485 certification and progresses towards IVDR certification, positioning Lodestar DX for upcoming commercial launches across Europe for treatment-directing diagnosis of urinary tract infections (UTIs). Bob Yang joins Llusern Scientific as Chief Medical Officer. A highly accomplished urology consultant, Mr. Yang brings extensive expertise in complex and recurrent UTIs and male and female incontinence. He has made significant contributions to antibiotic-free treatment options for recurrent UTIs and has been pioneering research in sub-lingual UTI vaccines and male incontinence devices. His expertise will directly complement Llusern's mission to revolutionize UTI diagnostics and support antimicrobial stewardship through the Lodestar DX system, a rapid diagnostic platform designed to enhance clinical decision-making. He is Lead Editor for Springer Nature academic textbooks on Urinary Tract Infections and Male Incontinence, solidifying his standing as one of the global leaders in urological research and practice. Mr. Yang continues to pioneer in his field as a urology consultant at the Royal Berkshire NHS Foundation Hospital and an Associate Lecturer at Oxford University. 'Joining Llusern Scientific is an exciting opportunity to contribute to the growth of innovative diagnostic solutions that will improve patient outcomes globally,' said Bob Yang, Chief Medical Officer of Llusern Scientific. 'The Lodestar DX system offers clinicians a powerful tool to make precise treatment decisions in a single visit, thereby enabling them to combat antimicrobial resistance through improved antibiotic stewardship.' As Chief Financial Officer, Maddy Kennedy brings over 25 years of experience in financial strategy, investor relations, and corporate governance to Llusern Scientific. She will play a crucial role in supporting Llusern's fundraising activities and steering its expansion into global markets. Known for her ability to translate complex development programs into clear financial plans, Maddy has successfully guided life sciences and technology businesses through strategic growth, M&A, IPOs, and exit planning. Her leadership roles at companies such as Maxwellia, Kesmalea Therapeutics, and Psioxus Therapeutics have equipped her with expertise in scaling operations and securing funding. She brings strong governance expertise from Non-Executive Director roles at Nuformix plc, Heartbeat CIC, and Tetris Pharma. She is currently also CFO at PBD Biotech and Fermtech. 'I am excited to join Llusern Scientific at this crucial stage of its development,' said Maddy Kennedy, Chief Financial Officer of Llusern Scientific. 'With its innovative Lodestar DX system poised for expansion into new markets, I look forward to supporting Llusern's growth and overseeing the financial operations needed to achieve its global ambitions.' Mark Preston joins Llusern Scientific as Chief Technology Officer, bringing extensive expertise in biotech, data analytics, and cloud technologies. As CTO, Mark will lead the development of Lodestar DX overseeing technological innovation, scalability, and compliance. Mark's early career includes experience in embedded systems and devices at Sony and Panasonic, working on networking hardware, mobile phones, and microscopes. His later work in app development, AI-driven insights, and workflow optimization enabled him to deliver scalable, secure, and compliant solutions for start-ups and global organizations, including vaccine manufacturers. As a Founder and Managing Director of consultancy firm Prismea, Mark helps biotech companies innovate with data analytics, cloud systems, and regulatory compliance as well as navigating medical regulatory frameworks with organizations such as the MHRA. 'I've been impressed by the Lodestar DX system and its ability to deliver treatment directing diagnosis of UTIs at the point of care,' said Mark Preston, Chief Technology Officer. 'I look forward to supporting the company's efforts to bring precision diagnostics to healthcare settings worldwide.' Emma Hayhurst, Co-founder and CEO of Llusern Scientific, commented:'We are thrilled to welcome Bob, Maddy, and Mark to our executive leadership team. Their deep expertise in urology, finance, and technology will be instrumental in ensuring Llusern remains at the forefront of providing precise, accessible diagnostic solutions that deliver improved outcomes for patients suffering from UTIs.' Notes to Editors About Llusern ScientificLlusern Scientific is a treatment-directing molecular diagnostics company, developing fast, accurate, and accessible tools to guide real-time clinical decision-making at the point-of-care. Our flagship solution, Lodestar DX, is a portable diagnostic device that delivers lab-accurate results for urinary tract infections (UTIs) in around half an hour. It is based on isothermal LAMP technology (not PCR) without the need for DNA extraction or centralized lab infrastructure. With industry-leading sensitivity and specificity, Lodestar DX empowers clinicians to diagnose and treat specific microbial infections with precision in a single visit, thereby improving patient outcomes. As well as providing guidance on the best treatment option based on the specific microbial infection, Lodestar DX also provides a clear 'rule-out' decision where antibiotics are not necessary, helping to reduce antimicrobial resistance through antibiotic stewardship. Building on success in the UK, Llusern is preparing for commercial launches across India and the MENA region in 2025 and the US in 2026. Llusern is committed to transforming diagnostic pathways and making precision medicine equitable, portable, and fast. Due to its small size and ease of portability Lodestar DX is particularly suitable for resource limited and decentralised healthcare settings including care homes, mobile diagnostics, and community diagnostic centres. Additionally Lodestar DX has uses within paediatrics, urology, and other secondary care settings. The Lodestar DX UTI testing system has been independently evaluated in studies by University of Oxford, Norfolk and Norwich University Hospital, Southampton University, and Public Health Wales. The company was established in 2020 as a spin-out from the University of South Wales, UK. For more information, visit and follow us on LinkedIn. Media Contacts Llusern ScientificMartyn Lewis +44 (0) 7825 708936martyn@ Scius CommunicationsKatja Stout +44 (0) 7789435990katja@ Daniel Gooch +44 (0) 7747875479daniel@ in to access your portfolio


Medscape
2 hours ago
- Medscape
QoL Deserves More Than a Footnote in Cancer Trials
In a review published in New England Journal of Medicine Evidence , Massimo Di Maio, MD, from the Department of Oncology at the University of Turin in Turin, Italy, and president-elect of the Italian Association of Medical Oncology, offers a detailed analysis of how patient-reported outcomes are used in clinical trials and explains the best practices for interpreting quality-of-life (QoL) data. 'QoL data are increasingly being included in oncology trials,' Di Maio told Univadis Italy, a Medscape Network platform. 'However, the scientific community is less familiar with interpreting — or critically assessing — this type of data compared with more traditional endpoints like progression-free survival or overall survival.' With growing support from scientific societies and regulatory agencies, QoL has become a standard endpoint in many studies. Yet practical guidance on its interpretation remains limited. Di Maio, who also served as lead author of the European Society For Medical Oncology guidelines on the use of patient-reported outcome measures in oncology, views this as a significant gap in the field. 'We must not forget that for many patients — especially those in advanced stages of disease — living well can be just as important, if not more so, than living longer,' he emphasized. He also cautioned that statistical significance does not always translate into meaningful clinical benefit. From Trial Design... To accurately assess QoL and maximize the value of the data, clinical trials must be appropriately designed from the outset. As outlined in the article, phase 3 randomized trials offer the ideal framework for QoL measurement. They allow investigators to compare results between treatment and control groups, tracking changes from baseline and over time. Di Maio explains in the review that randomized trial designs help ensure that any differences observed between study arms are directly linked to the treatment itself. Speaking with Univadis Italy , he also addressed the potential for bias in QoL data collection. 'Some researchers argue that simply knowing they are receiving the experimental treatment may lead patients — perhaps even subconsciously — to perceive a benefit, which could influence patient-reported outcomes like QoL,' he said. Still, Di Maio noted the difficulty in rigorously proving the existence or magnitude of such bias. Ideally, this would be tested by comparing blinded and open-label trials, but these studies are uncommon and logistically challenging. One coordinated analysis, led by Fabio Efficace, PhD, of the Italian Group for Adult Hematologic Diseases, found that trial blinding was not an independent predictor of QoL benefit. While the potential for bias cannot be dismissed, Di Maio believes its real-world impact is likely modest — and that open-label studies can still yield valid and meaningful QoL data. ...To Data Interpretation Few oncology trials designate QoL as a primary endpoint, but this isn't inherently a limitation, Di Maio noted. QoL can still be a valuable secondary endpoint — provided the results are interpreted carefully and in the proper context. One of the central challenges is patient compliance with QoL questionnaires, which tends to be inconsistent. Factors contributing to low completion rates include limited time for clinicians to communicate the importance of QoL data, patient dropout due to disease progression or adverse outcomes, and technical issues such as failures in electronic data capture or patients' unfamiliarity with digital tools. In such cases, Di Maio suggested that having a paper-based backup system can improve data reliability. Ultimately, QoL should not be viewed as an optional or secondary concern, but as a fundamental part of assessing the true value of cancer therapies. Patient-reported outcome measures, while designed to capture quality of life, also offer critical insights into the broader effectiveness and utility of treatments. 'QoL data alone aren't sufficient,' Di Maio emphasized, 'but they are indispensable for understanding the value of a therapy — and for communicating that value clearly to patients.' He concluded that interpreting QoL data accurately is not just a scientific imperative but also an ethical obligation to patients navigating serious and often life-limiting conditions.